Efficacious control of cytomegalovirus infection after long-term depletion of CD8+ T lymphocytes.
about
Mutual Interference between Cytomegalovirus and Reconstitution of Protective Immunity after Hematopoietic Cell TransplantationImmunobiology of congenital cytomegalovirus infection of the central nervous system—the murine cytomegalovirus modelControl of murine cytomegalovirus infection by γδ T cellsComparison of OX40 ligand and CD70 in the promotion of CD4+ T cell responsesSelf MHC class I-licensed NK cells enhance adaptive CD8 T-cell viral immunity.Human Cytomegalovirus Induces Cellular and Humoral Virus-specific Immune Responses in Humanized BLT MiceMucosal and parenteral vaccination against acute and latent murine cytomegalovirus (MCMV) infection by using an attenuated MCMV mutant.Preemptive CD8 T-cell immunotherapy of acute cytomegalovirus infection prevents lethal disease, limits the burden of latent viral genomes, and reduces the risk of virus recurrence.Suppression of murine cytomegalovirus (MCMV) replication with a DNA vaccine encoding MCMV M84 (a homolog of human cytomegalovirus pp65)Controlling cytomegalovirus: helping the immune system take the leadCD4+ T-cell reconstitution reduces cytomegalovirus in the immunocompromised brainGamma interferon-dependent clearance of cytomegalovirus infection in salivary glandsAbsence of cross-presenting cells in the salivary gland and viral immune evasion confine cytomegalovirus immune control to effector CD4 T cells.CD8+ T lymphocytes control murine cytomegalovirus replication in the central nervous system of newborn animals.The M33 G protein-coupled receptor encoded by murine cytomegalovirus is dispensable for hematogenous dissemination but is required for growth within the salivary gland.Development of a vaccine against murine cytomegalovirus (MCMV), consisting of plasmid DNA and formalin-inactivated MCMV, that provides long-term, complete protection against viral replicationRecombinant mouse cytomegalovirus expressing a ligand for the NKG2D receptor is attenuated and has improved vaccine properties.Vigorous innate and virus-specific cytotoxic T-lymphocyte responses to murine cytomegalovirus in the submaxillary salivary gland.Immunogenicity of cytopathic and noncytopathic viral vectorsStrong CD8 T-cell responses following coimmunization with plasmids expressing the dominant pp89 and subdominant M84 antigens of murine cytomegalovirus correlate with long-term protection against subsequent viral challengeGain of virulence caused by loss of a gene in murine cytomegalovirusMast cells expedite control of pulmonary murine cytomegalovirus infection by enhancing the recruitment of protective CD8 T cells to the lungs.Human cytomegalovirus (HCMV)-specific CD4+ and CD8+ T cells are both required for prevention of HCMV disease in seropositive solid-organ transplant recipients.Adoptive transfer of T lymphocytes to T-cell-depleted mice inhibits Escherichia coli translocation from the gastrointestinal tract.Memory T cells persisting in the brain following MCMV infection induce long-term microglial activation via interferon-γ.CXCR3-dependent recruitment of antigen-specific T lymphocytes to the liver during murine cytomegalovirus infection.Anti-human cytomegalovirus activity of cytokines produced by CD4+ T-cell clones specifically activated by IE1 peptides in vitro.DNA immunization confers protection against murine cytomegalovirus infection.Cytomegalovirus in hematopoietic stem cell transplant recipientsThe Cellular Localization of Human Cytomegalovirus Glycoprotein Expression Greatly Influences the Frequency and Functional Phenotype of Specific CD4+ T Cell Responses.Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus.CD4(+) T cell subsets during virus infection. Protective capacity depends on effector cytokine secretion and on migratory capability.Human cytomegalovirus inhibits major histocompatibility complex class II expression by disruption of the Jak/Stat pathway.Murine cytomegalovirus inhibits interferon gamma-induced antigen presentation to CD4 T cells by macrophages via regulation of expression of major histocompatibility complex class II-associated genes.Interferon gamma regulates acute and latent murine cytomegalovirus infection and chronic disease of the great vessels.Endogenous human cytomegalovirus gB is presented efficiently by MHC class II molecules to CD4+ CTLCross-protection against lymphocytic choriomeningitis virus mediated by a CD4+ T-cell clone specific for an envelope glycoprotein epitope of Lassa virus.CD4 T cell responses in latent and chronic viral infections.Cutting edge: murine cytomegalovirus induces a polyfunctional CD4 T cell response.Reconstitution of CD8 T Cells Protective against Cytomegalovirus in a Mouse Model of Hematopoietic Cell Transplantation: Dynamics and Inessentiality of Epitope Immunodominance.
P2860
Q26740328-4C2B91BA-4444-4922-A88B-397A6681BAC3Q27026924-2EA0626B-48DF-49B4-9A07-73CEECA59888Q27322847-D321645E-4B76-4BAE-8D44-C4FF9E55FDBDQ28507643-19AB7AD5-BDCB-4704-96EB-4BE34ECD2BCDQ30426938-9F15E429-168A-46D5-BA03-D10B0E238BA5Q33681388-F18FEBAC-9630-4DBE-862C-34F1DDB712DCQ33782029-AE591FC9-6CD8-4DEF-ABAA-9788C0E6BCDAQ33782273-5EC6F213-96FC-4EE2-9C06-7C6F29CC9491Q33802461-812147E5-E90F-4AFA-B8ED-E91EE4DB3298Q33820695-AC87A317-B32A-46F2-900B-6B01D23D1FFCQ33908883-5CCB1971-26BB-40B8-BC33-956085E42B12Q33930607-07313CA7-4466-4320-B083-23CA4F7A6372Q34013634-FA12DB0E-0176-4DA2-A055-CE3D3E5DE15FQ34166586-E3DCCF4D-80D8-4396-BD44-B1EAF1425858Q34261510-691EADB0-76A6-419D-96C6-6AC9D794BA94Q34338715-2040F500-8C37-4A29-9CE6-3979DBDE7DD7Q34360228-9EC59742-FEC2-41C6-BABB-C7EF8E252326Q34465970-3D89AF03-BB16-474A-8237-ED0E9782B5B2Q34716855-53AD93C0-46DA-4636-A7B3-69FFB678E62CQ34970937-A02B3B74-B5E0-4A9E-B147-5A7C0C8DC549Q35123311-6B18A070-BA97-44B0-9203-4112CE787B58Q35157254-C4B377FB-8340-455C-A8E2-BA8FCD07B9F3Q35233773-470A47FE-5309-4954-A727-F2DABA80D64CQ35441656-D02CA3BC-241A-4AAB-AFE3-72067C57CBB8Q35476157-FC645927-0485-40A4-B031-D5963EFECB4CQ35635259-547327EF-D3C1-4D40-ACC8-DD883BA221A6Q35858429-52CB304D-DD4D-4720-A528-ADBC8CE0D27DQ35872388-EA5989ED-B05C-4490-9EDD-D417BB223C7BQ35922928-2B73290F-0B3C-40BA-9F9C-5EBB74B6E19DQ36116754-19E3C1E6-48F4-4B90-9FF2-49A20EB710A9Q36363051-7302F83C-191B-4F3C-B8B2-31611BE43902Q36368586-AD1417C3-3918-4D6F-B92E-C1EE4C67EFD3Q36400431-095C8CD8-7D03-4EA2-829C-E82D9C546D22Q36400586-91B8510C-25FF-462A-8856-FE6EB671E281Q36401507-F8164580-CA60-4808-A14C-E5A160E18ADCQ36403664-950D4C88-49B0-4C71-8AD4-E84DF273497DQ36648449-89D84442-9B80-4170-841C-9E23769CE72AQ36837631-D4EC97BC-B8D0-4578-9BD4-947786B147A4Q36983075-2733E422-45C6-4467-9A93-841C6DCE6D26Q36999665-71E5CA3E-C002-4B5D-B8DE-55D17CB93547
P2860
Efficacious control of cytomegalovirus infection after long-term depletion of CD8+ T lymphocytes.
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
1990年论文
@zh
1990年论文
@zh-cn
name
Efficacious control of cytomeg ...... pletion of CD8+ T lymphocytes.
@ast
Efficacious control of cytomeg ...... pletion of CD8+ T lymphocytes.
@en
type
label
Efficacious control of cytomeg ...... pletion of CD8+ T lymphocytes.
@ast
Efficacious control of cytomeg ...... pletion of CD8+ T lymphocytes.
@en
prefLabel
Efficacious control of cytomeg ...... pletion of CD8+ T lymphocytes.
@ast
Efficacious control of cytomeg ...... pletion of CD8+ T lymphocytes.
@en
P2093
P2860
P1433
P1476
Efficacious control of cytomeg ...... pletion of CD8+ T lymphocytes.
@en
P2093
P2860
P304
P407
P577
1990-11-01T00:00:00Z